Risk Assessment Approach to Microbiological Controls of Cell Therapies

References

1. 1.↵
   U.S. Congress. 21 U.S. Code Chapter 9--Federal Food, Drug, and Cosmetic Act. https://uscode.house.gov (accessed Dec 10, 2019).
2. 2.↵
   United States Congress. 42 U.S.C. Chapter 6A--Public Health Service. https://uscode.house.gov (accessed Dec 10, 2019).
3. 3.↵
   U.S. Food and Drug Administration. Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products. Fed Regist. 1993, 58 (197), 53248–53251.

   OpenUrl
4. 4.↵
   CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancer, 2017. National Cancer Institute Web Site. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells#evolution. (accessed Dec 10, 2019).
5. 5.↵
   European Commission, EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice: Guidelines on Good Manufacture Practice Specific to Advanced Therapeutic Medicinal Products. European Commission: Brussels, 2018.
6. 6.↵
   European Medicines Agency, Guideline on Human Cell-Based Medicinal Products. EMA: London, 2008.
7. 7.↵
   Friends of Cancer Research and Parker Institute for Cancer Immunotherapy. Designing the Future of Cell Therapies, 2019. Friends of Cancer Research Web site. https://www.focr.org/sites/default/files/pdf/Friends_Cellular_Therapies_White_Paper.pdf (accessed Dec 10, 2019).
8. 8.↵
   1. Mahmood A.,
   2. Ali S.

   Microbial and Viral Contamination of Animal and Stem Cell Cultures: Common Contaminants, Detection, and Elimination. J. Stem Cell Res. Ther. 2017, 2 (5), 1–8.

   OpenUrl
9. 9.↵
   Parenteral Drug Association Inc. Technical Report No. 81: Cell-based Therapy Control Strategy; Bethesda, MD, 2019.
10. 10.↵
    U.S. Food and Drug Administration, 21 CFR Part 1271—Human Cells, Tissues, and Cellular and Tissue-Based Products. U.S. Department of Health and Human Services. Government Publishing Office: Washington, D.C., 2019.
11. 11.↵
    1. Agallaco J.

    Agallaco & Associates, Bell Mead, NJ. Personal Communication, 2019.
12. 12.↵
    U.S. Pharmacopeial Convention, General Chapter <71> Sterility Tests. https://www.uspnf.com (accessed Dec 10, 2019).
13. 13.↵
    U.S. Food and Drug Administration, Draft Guidance for Industry: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2018.
14. 14.↵
    U.S. Pharmacopeial Convention, General Chapter <1071> Rapid Sterility Testing of Short Life Products: A Risk Based Approach. https://www.uspnf.com (accessed Dec 10, 2019).
15. 15.↵
    U.S. Pharmacopeial Convention, General Chapter <63> Mycoplasma Tests. https://www.uspnf.com (accessed Dec 10, 2019).
16. 16.↵
    U.S. Pharmacopeial Convention, General Chapter <85> Bacterial Endotoxins Test. https://www.uspnf.com (accessed Dec 10, 2019).